Viridian Therapeutics, Inc.\DE SEC filings VRDN
Viridian Therapeutics, Inc.\DE has 817 filings in SEC EDGAR's recent list, going back to Nov 12, 2013. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 305B2 | Filing | May 7, 2026 | — |
| EFFECT | Filing | Nov 17, 2021 | — |
| CORRESP | Letter to the SEC | Nov 15, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2021 | — |
| EFFECT | Filing | Dec 22, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2020 | — |
| CORRESP | Letter to the SEC | Dec 21, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2020 | — |
| CORRESP | Letter to the SEC | Dec 8, 2020 | — |
| PRER14A | Filing | Dec 8, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2020 | — |
| D | Filing | Nov 6, 2020 | — |
| EFFECT | Filing | Apr 14, 2020 | — |
| CORRESP | Letter to the SEC | Apr 10, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 18, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 6, 2020 | — |
| D/A | Filing | Oct 31, 2019 | — |
| SEC STAFF LETTER | Filing | Jul 11, 2019 | — |
| SEC STAFF LETTER | Filing | Jul 3, 2019 | — |
| CT ORDER | Filing | Nov 19, 2018 | — |
| CT ORDER | Filing | Aug 20, 2018 | — |
| D | Filing | Aug 6, 2018 | — |
| CT ORDER | Filing | May 22, 2018 | — |
| D | Filing | Nov 22, 2017 | — |
| CT ORDER | Filing | Nov 20, 2017 | — |
| CT ORDER | Filing | Nov 14, 2017 | — |
| CT ORDER | Filing | Aug 28, 2017 | — |
| CT ORDER | Filing | Jun 19, 2017 | — |
| EFFECT | Filing | Apr 25, 2017 | — |
| CT ORDER | Filing | Jan 11, 2017 | — |
| EFFECT | Filing | Jan 9, 2017 | — |
| 425 | 8-k | Jan 9, 2017 | — |
| CORRESP | Letter to the SEC | Jan 6, 2017 | — |
| 425 | Form 8-k | Dec 1, 2016 | — |
| 425 | Form 8-k | Nov 29, 2016 | — |
| 425 | Form 8-k | Nov 28, 2016 | — |
| 425 | Form 8-k | Nov 3, 2016 | — |
| 425 | Form 8-k | Nov 2, 2016 | — |
| 425 | Form 8-k | Nov 1, 2016 | — |
| EFFECT | Filing | Dec 2, 2015 | — |
| EFFECT | Filing | Dec 2, 2015 | — |
| EFFECT | Filing | Dec 2, 2015 | — |
| CORRESP | Letter to the SEC | Dec 2, 2015 | — |
| CORRESP | Letter to the SEC | Nov 20, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2015 | — |
| EFFECT | Filing | Jul 28, 2015 | — |
| CORRESP | Letter to the SEC | Jul 24, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 20, 2015 | — |
| EFFECT | Filing | Feb 17, 2015 | — |
| CT ORDER | Filing | Jan 14, 2015 | — |
| CT ORDER | Filing | Nov 24, 2014 | — |
| CT ORDER | Filing | Oct 9, 2014 | — |
| CT ORDER | Filing | Sep 5, 2014 | — |
| CT ORDER | Filing | Jul 21, 2014 | — |
| EFFECT | Filing | Jun 17, 2014 | — |
| CORRESP | Letter to the SEC | Jun 16, 2014 | — |
| CORRESP | Letter to the SEC | Jun 16, 2014 | — |
| CORRESP | Letter to the SEC | Jun 12, 2014 | — |
| CORRESP | Letter to the SEC | Jun 12, 2014 | — |
| CORRESP | Letter to the SEC | Jun 9, 2014 | — |
| CORRESP | Letter to the SEC | Jun 9, 2014 | — |
| CERTNAS | Auto-generated paper document | Jun 9, 2014 | — |
| 8-A12B | Filing | Jun 6, 2014 | — |
| CORRESP | Letter to the SEC | Jun 2, 2014 | — |
| UPLOAD | Letter from the SEC | May 30, 2014 | — |
| CORRESP | Letter to the SEC | May 27, 2014 | — |
| UPLOAD | Letter from the SEC | May 22, 2014 | — |
| CORRESP | Letter to the SEC | Apr 9, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2014 | — |
| CORRESP | Letter to the SEC | Mar 18, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2014 | — |
| DRS/A | Filing | Feb 14, 2014 | — |
| DRSLTR | Filing | Feb 13, 2014 | — |
| DRSLTR | Filing | Jan 30, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2014 | — |
| DRSLTR | Filing | Dec 30, 2013 | — |
| DRS/A | Filing | Dec 30, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2013 | — |
| DRS | Filing | Nov 12, 2013 | — |
Showing 80 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC. (until Jan 15, 2021); SIGNAL GENETICS, INC. (until Feb 10, 2017); SIGNAL GENETICS LLC (until Jul 9, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.